Development Of DNA Targeted Platinum Agents As Potential Anticancer Drugs
Funder
National Health and Medical Research Council
Funding Amount
$410,250.00
Summary
A number of clinically useful anticancer drugs damage DNA. As a result of this damage these drugs kill cancer cells. This project aims to develop new platinum-containing compounds which are specifically targeted to DNA. Through this strategy it is possible that new and more useful anticancer drugs could emerge.
Using Next-generation Sequencing Technology To Explore The Genetic Basis Of Human Disease
Funder
National Health and Medical Research Council
Funding Amount
$278,463.00
Summary
This project will use powerful new DNA sequencing technologies to analyse the genes that underlie common diseases such as diabetes, arthritis and cancer in a large and diverse set of human DNA samples, and to find mutations in Australian patients suffering from rare genetic muscle disorders. This approach will provide novel information about the evolutionary origins and genetic basis of common disease and identify new genes that cause inherited muscle diseases.
Identification And Characterisation Of Genes Causing Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) And Related Phenotypes
Funder
National Health and Medical Research Council
Funding Amount
$376,640.00
Summary
Epilepsy affects approximately 2% of the population at some stage of their lives. We have recently identified two new genes involved in the development of a type of epilepsy known as ADNFLE. We aim to identify further epilepsy genes by sequencing ADNFLE patients who do not yet have identified mutations. We also aim to identify the genes interacting with the genes we have identified, increasing our understanding of the cellular networks involved in the development of epilepsy.
Analysis Of Circulating Tumour DNA For Mutational Characterisation And Tracking Disease Progression In Multiple Myeloma
Funder
National Health and Medical Research Council
Funding Amount
$908,676.00
Summary
Multiple myeloma is cancer of plasma cells in the bone marrow and presents at multiple sites with dissimilar genetic information (GI) across these sites. Invasive biopsies of multiple sites are required to determine the GI. Cancer cells shed small amounts of DNA into the blood stream and this circulating DNA (ctDNA) contains GI from multiple cancer sites. This project will evaluate the utility of ctDNA to determine GI and to predict treatment response in MM patients.
Massive Parallel Sequencing In The Genetics Of Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
Epilepsy is a serious disorder which affects approximately 2% of the population at some stage in their life and around 30% of patients do not gain adequate control of their seizures with medications presently available. Approximately 70% of epilepsy in inherited and so far the majority of the genetic causes are yet to be discovered. My group aims to identify new epilepsy genes. This leads to improved diagnosis, treatment and counseling for patients and increased understanding of the biological m ....Epilepsy is a serious disorder which affects approximately 2% of the population at some stage in their life and around 30% of patients do not gain adequate control of their seizures with medications presently available. Approximately 70% of epilepsy in inherited and so far the majority of the genetic causes are yet to be discovered. My group aims to identify new epilepsy genes. This leads to improved diagnosis, treatment and counseling for patients and increased understanding of the biological mechanisms underlying seizures.Read moreRead less
Defining Genomic Mechanisms Associated With Treatment Response, Drug Resistance And Early Blast Crisis In Chronic Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Chronic myeloid leukaemia is a fatal disease if untreated. Most patients now survive with new drugs, but some still rapidly die. I aim to understand these differences by investigating the genetic makeup of patients at diagnosis. Some may have gene mutations that prevent drugs from working effectively. Mutations will be detected using technology that can search more than 30,000 genes at the same time. This work could lead to improved survival for more patients by finding new targets for therapy.
New Technologies For Hierarchial Shotgun Sequencing Of Recalcitrant And Repetitive DNA
Funder
National Health and Medical Research Council
Funding Amount
$79,750.00
Summary
Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetit ....Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetitive DNA fragments in genomes.Read moreRead less